Etienne Becht1,2,3,4, Nicolas A Giraldo1,2,3, Laetitia Lacroix1,2,3, Bénédicte Buttard1,2,3, Nabila Elarouci4, Florent Petitprez1,2,3,4, Janick Selves5,6, Pierre Laurent-Puig7, Catherine Sautès-Fridman1,2,3, Wolf H Fridman1,2,3, Aurélien de Reyniès8. 1. INSERM UMR_S 1138, Cancer, Immune Control and Escape, Cordeliers Research Centre, Paris, France. 2. Université Paris Descartes, Paris, France. 3. Université Pierre et Marie Curie, Paris, France. 4. Programme Cartes d'Identité des Tumeurs, Ligue Nationale Contre le Cancer, Paris, France. 5. Centre de Recherche en Cancérologie de Toulouse, Unité Mixte de Recherche, 1037 INSERM, Université Toulouse III, Toulouse, France. 6. Department of Pathology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. 7. INSERM, UMR_S1147, Paris, France. 8. Programme Cartes d'Identité des Tumeurs, Ligue Nationale Contre le Cancer, Paris, France. Aurelien.DeReynies@ligue-cancer.net.
After the publication of this work [1] it was noticed that the legend of Fig. 1a was incorrect. The correct legend should read: Flowchart of MCP-counter’s development and validation. It was also noted that in Fig. 2c the name of the last two genes was partially removed. The horizontal lines that were delineating the specificity of the displayed genes are missing. The corrected Fig. 2c is noted below.
Fig. 2
Identification and qualitative validation of transcriptomic markers. a The MCP discovery series. pDC plasmacytoid dendritic cell, PBMC peripheral blood mononuclear cell. b Quartiles of MCP-counter scores on positive and control samples in the discovery and validation microenvironment series. Gray indicates missing values. c Representative transcriptomic markers and their corresponding expression patterns in the MCP discovery series
Identification and qualitative validation of transcriptomic markers. a The MCP discovery series. pDC plasmacytoid dendritic cell, PBMC peripheral blood mononuclear cell. b Quartiles of MCP-counter scores on positive and control samples in the discovery and validation microenvironment series. Gray indicates missing values. c Representative transcriptomic markers and their corresponding expression patterns in the MCP discovery seriesThe equal contributors symbol was missing for authors Aurélien de Reyniès and Wolf H. Fridman. This has now been corrected.In the PDF version of the article, equation 5 in the section ‘Correlation profiles of TM in microenvironment and tumor datasets’ is incorrect. Please see the correct equation below:The publisher apologises for these errors.
Authors: Karsten Krug; Eric J Jaehnig; Shankha Satpathy; Lili Blumenberg; Alla Karpova; Meenakshi Anurag; George Miles; Philipp Mertins; Yifat Geffen; Lauren C Tang; David I Heiman; Song Cao; Yosef E Maruvka; Jonathan T Lei; Chen Huang; Ramani B Kothadia; Antonio Colaprico; Chet Birger; Jarey Wang; Yongchao Dou; Bo Wen; Zhiao Shi; Yuxing Liao; Maciej Wiznerowicz; Matthew A Wyczalkowski; Xi Steven Chen; Jacob J Kennedy; Amanda G Paulovich; Mathangi Thiagarajan; Christopher R Kinsinger; Tara Hiltke; Emily S Boja; Mehdi Mesri; Ana I Robles; Henry Rodriguez; Thomas F Westbrook; Li Ding; Gad Getz; Karl R Clauser; David Fenyö; Kelly V Ruggles; Bing Zhang; D R Mani; Steven A Carr; Matthew J Ellis; Michael A Gillette Journal: Cell Date: 2020-11-18 Impact factor: 41.582
Authors: J Fay; S Toomey; A J Eustace; S F Madden; D M Collins; E W Kay; K M Sheehan; S Furney; B Moran; A Fagan; P G Morris; A Teiserskiene; A D Hill; L Grogan; J M Walshe; O Breathnach; C Power; D Duke; K Egan; W M Gallagher; N O'Donovan; J Crown; B T Hennessy Journal: Breast Cancer Res Treat Date: 2021-05-13 Impact factor: 4.872
Authors: YiHeng Du; WenHao Miao; Xiang Jiang; Jin Cao; Bo Wang; Yi Wang; Jiang Yu; XiZhi Wang; HaiTao Liu Journal: Front Oncol Date: 2021-06-03 Impact factor: 6.244